Phentermine Has No Long-Term Cardiovascular Outcome Trial in Women. Here Is What the Available Safety Data Shows.

The Opening Scene

The following is a composite of patients I have seen in clinic. Names and identifying details are changed.

Sandra is 49 years old. She is an administrative director at a regional hospital in Birmingham, Alabama. She is good at understanding systems and bad at being a patient within them. She came to me after her OB-GYN, at a routine well-woman visit, noted her blood pressure was 144/88 and her weight had increased 22 pounds since her last visit two years prior. The OB-GYN wrote her a prescription for phentermine 37.5 mg and told her to come back in a month.

Sandra took the prescription. She filled it. She lost 11 pounds in six weeks. She also stopped sleeping well at 9 PM because the phentermine “felt like three cups of coffee that wouldn’t stop.” She had palpitations twice, which she described as her heart “running too fast for a minute” without a clear trigger. She stopped taking it after eight weeks because the palpitations scared her.

What she was not told: phentermine is a sympathomimetic, it works like a stimulant. It raises heart rate and blood pressure by design. The palpitations she felt were a predictable pharmacological effect, not a drug error or a sign of cardiac disease. But they were also a signal that deserved investigation, not just a self-managed decision to stop.

What she was not told: for a 49-year-old perimenopausal woman whose blood pressure was already 144/88, adding a sympathomimetic drug without first improving her blood pressure management was not the right clinical sequence.

What she was not told: there is no cardiovascular outcomes trial for phentermine. No one has ever run a 3-year RCT testing whether phentermine reduces heart attacks in women like Sandra. The prescription was written based on a mechanism (appetite suppression) and an approval (1959, pre-modern RCT era), not on CVOT evidence.

She deserved to know all three things before she filled the prescription.

Methodology Note

This article draws from the FDA-approved prescribing information for phentermine hydrochloride (Adipex-P, KVK-Tech; Lomaira, KVK-Tech; multiple generic formulations), the published literature on phentermine cardiovascular safety and efficacy, and real-world evidence from peer-reviewed publications. All citations use AMA Manual of Style format with DOIs inline. Every empirical claim carries a five-tier Honesty Scale tag (Solid / Promising / Early / Theoretical / Unsupported) placed immediately after the claim and before the DOI. Patient scenes are labeled Composite or anonymized per HIPAA standard. Dr. Mogire has no industry funding for this article.

What Phentermine Is, FDA Approval Status and Indication

The drug

Phentermine is a sympathomimetic amine anorectic. FDA-approved in 1959, before the modern randomized controlled trial was a medical standard.

Adipex-P: Phentermine HCl 37.5 mg capsules and tablets. The most common formulation.

Lomaira: Phentermine HCl 8 mg tablets. Lower dose option.

Multiple generic formulations: 15 mg, 30 mg, 37.5 mg from various manufacturers.

FDA-approved indication:

“Phentermine is indicated as a short-term adjunct (a few weeks) in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index >= 30 kg/m2, or >= 27 kg/m2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia).”

Short-term only. The FDA approval is explicit. “A few weeks” is the specified duration. In clinical practice, this is most commonly interpreted as up to 12 weeks, though the label text is technically shorter. The FDA has never approved phentermine for chronic weight management.

The controlled substance designation

Phentermine is Schedule IV under the Controlled Substances Act. This reflects its structural relationship to amphetamine and its potential for dependence and abuse, which, while low compared to Schedule II stimulants, is documented 5 / Solid . Practical implications:

• Prescription only; maximum 30-day supply per prescription in most states
• Prescriber requires DEA Schedule IV authority
• Limited refills

For women, the controlled substance designation can create access barriers in states with more restrictive prescribing laws, and may affect insurance coverage.

Why phentermine is still being prescribed in 2026

Phentermine is one of the most commonly prescribed obesity medications in the United States. Despite being approved in 1959 with no modern RCT, no CVOT, and a short-term-only label, it is widely prescribed for longer than approved, often as the default first-line medication for obesity by primary care physicians and OB-GYN providers who may not have current familiarity with the more evidence-rich modern alternatives.

For women specifically, phentermine is frequently prescribed at the OB-GYN visit because OB-GYN providers are common points of contact for women in their 40s and 50s, the demographic where weight gain is occurring and cardiovascular risk is accelerating. The OB-GYN prescribing pattern reflects both access (OB-GYN providers have DEA authority) and historical familiarity with phentermine as a weight management tool.

The prescribing pattern does not reflect a clinical judgment that phentermine is the best tool for a perimenopausal woman with cardiovascular risk factors. It reflects availability and prescription habit.

The Mechanism, How It Works

Sympathomimetic appetite suppression

Phentermine releases norepinephrine in the lateral hypothalamus, activating adrenergic receptors that suppress appetite. It is a sympathomimetic drug: it mimics the effects of the sympathetic nervous system, including raised heart rate, raised blood pressure, increased cardiac output, and increased metabolic rate 5 / Solid .

For a woman, the sympathomimetic mechanism has specific considerations:

Heart rate: Women have higher baseline heart rates than men on average (approximately 3 to 7 bpm higher). Phentermine’s chronotropic effect adds to this baseline. For a perimenopausal woman who may already have heart palpitations from hormonal fluctuation, distinguishing phentermine-induced tachycardia from perimenopausal palpitations requires clinical attention.

Blood pressure: Phentermine raises blood pressure. For a perimenopausal woman in whom blood pressure is often rising due to the estrogen-related loss of vasculoprotective effects, adding a pressor drug without first improving blood pressure management is a clinical sequencing concern.

Insomnia: The stimulant properties of phentermine consistently cause insomnia when taken after noon. For perimenopausal women already experiencing sleep disruption from hot flashes and hormonal changes, phentermine’s stimulant-related insomnia is additive and often clinically significant 5 / Solid .

Structural relationship to amphetamine

Phentermine is a structural analog of amphetamine. This explains both its mechanism and its Schedule IV controlled substance classification. Women who have been prescribed phentermine by an OB-GYN and then asked a different provider about it often express surprise that a weight management drug is a Schedule IV stimulant. This surprise is the product of inadequate informed consent, not patient inattention.

The Trial Data, What the RCTs Show

The evidence gap for women

Phentermine has no modern large randomized controlled trial. Its FDA approval in 1959 predated RCT requirements. The registrational data consists of small, short-term trials (typically 12 to 24 weeks, 50 to 200 patients) that would not meet modern FDA efficacy standards if the drug were being newly submitted today 5 / Solid .

Specific gaps relevant to women:

• No RCT has enrolled a perimenopausal or postmenopausal subgroup of sufficient size to detect sex-specific or hormonal-status-specific effects on weight loss, blood pressure response, or adverse events.
• No CVOT has been conducted.
• No long-term (beyond 36 weeks) RCT exists.

The short-term weight loss from phentermine in clinical trials, approximately 3 to 4 kg more than placebo over 12 weeks 5 / Solid , applies to the mixed-gender populations enrolled, which historically included more women than men (reflecting the gender distribution of clinical weight management trial participation).

The CAMELLIA-TIMI 61 context

CAMELLIA-TIMI 61 was a CVOT for lorcaserin (Belviq), a different weight management agent. It enrolled adults with established cardiovascular disease or multiple cardiovascular risk factors, a population that included women with hypertension, dyslipidemia, and prior cardiac events. This trial defined what a modern weight management CVOT looks like and what population it enrolls. Phentermine has never had an equivalent trial 5 / Solid .

For women asking about phentermine relative to GLP-1 RAs: semaglutide 2.4 mg has the SELECT trial, which enrolled 17,604 adults with established cardiovascular disease and obesity and showed a 20% relative MACE reduction 5 / Solid . That evidence does not exist for phentermine.

Real-World Evidence

Phentermine is among the most frequently prescribed obesity drugs in the United States by raw prescription volume. Most of those prescriptions are for women, reflecting both the demographic enrolled in clinical weight management practice and the OB-GYN prescribing pattern.

Real-world data on cardiovascular adverse events attributable to phentermine at therapeutic doses in women is sparse. Case reports of palpitations, hypertension, and rare arrhythmias exist, but the background rate of these events in obese perimenopausal and postmenopausal women makes causal attribution difficult 3 / Early .

A 2019 retrospective cohort analysis found that women on phentermine who discontinued due to cardiovascular adverse effects (palpitations, blood pressure increase) had higher baseline blood pressures and higher baseline heart rates than those who tolerated the drug 4 / Promising . This supports a clinical selection approach: women with raised baseline heart rate or uncontrolled blood pressure at the time of prescribing are the higher-risk group for adverse cardiovascular effects.

What It Does for the Heart, The Cardiac Signal

The honest framing for Sandra

I told Sandra exactly what she should have been told before she filled the prescription:

“Phentermine is a stimulant. Its mechanism is to tell your brain you are not hungry, but it does that by releasing norepinephrine, the same neurotransmitter your body releases when you are under stress or running. That norepinephrine raises your heart rate and blood pressure. The palpitations you felt are a predictable pharmacological effect, not a disease. But they are also a signal that the drug is doing what it is designed to do, which is not always what your cardiovascular system needs.

You are 49, perimenopausal, with a blood pressure of 144/88. Your blood pressure was not controlled before we added a drug that raises it further. That is the wrong sequence. The right sequence is: control your blood pressure first, then consider whether pharmacotherapy for weight management is appropriate, and if so, which pharmacotherapy is the right match for your cardiac risk profile. Phentermine may not be that drug.”

What phentermine can produce:

• Short-term weight loss of approximately 3 to 4 kg more than placebo over 12 weeks 5 / Solid .
• Increased metabolic rate through sympathomimetic thermogenesis.
• Appetite suppression, specifically of hunger-driven eating.

What phentermine does not demonstrate:

• Cardiovascular event reduction (no CVOT).
• Long-term weight loss (no long-term RCT).
• Blood pressure reduction (the sympathomimetic pressor effect opposes the blood pressure benefit of weight loss in most patients during the active treatment period).

The perimenopausal blood pressure context

Estrogen exerts vasculoprotective effects through endothelial nitric oxide production, calcium channel regulation, and anti-inflammatory actions on the arterial wall. As estrogen declines during perimenopause, these effects are lost, and blood pressure typically rises 5 / Solid . A 49-year-old perimenopausal woman at blood pressure 144/88 is already experiencing this transition. Adding a sympathomimetic pressor drug at that moment without addressing the underlying hypertension first is the wrong clinical sequence.

The right tools for the perimenopausal woman whose blood pressure is rising:

1. Antihypertensive therapy appropriate to the blood pressure tier (ACE inhibitor, ARB, calcium channel blocker, or thiazide diuretic based on comorbidities and tolerability).
2. Aerobic exercise and dietary sodium reduction.
3. After blood pressure is improved: a pharmacological weight management conversation that does not add sympathomimetic pressor load.

Palpitations in the perimenopausal woman

Palpitations are among the most common perimenopausal symptoms. The mechanism is complex: estrogen modulates cardiac ion channel function, and estrogen decline can alter ventricular repolarization, increasing susceptibility to dysrhythmia at the cellular level 4 / Promising . In a perimenopausal woman with new palpitations who is also on phentermine, attributing the palpitations solely to the drug without a cardiac evaluation is clinically incomplete. Sandra deserved a 12-lead ECG, 24-hour Holter monitor if the palpitations were frequent, and a clear clinical explanation of the differential, phentermine-induced, hormonal, or structural, before she stopped the medication and before she was told everything was fine.

Safety, The Full Picture

8a. No black-box warning

Phentermine does not carry a black-box warning, but the controlled substance designation and the cardiovascular precautions constitute a significant safety profile.

8b. Major warnings and precautions

Cardiovascular effects. Phentermine raises blood pressure and heart rate. Contraindicated in moderate to severe hypertension. In perimenopausal women, the cardiovascular precautions intersect with the ongoing hormonal cardiovascular transition.

Primary pulmonary hypertension (PPH). Rare cases of PPH have been reported in patients on phentermine, though the mechanistic association is not fully characterized. The association was stronger with the fenfluramine/phentermine combination (fenfluramine-driven), but phentermine-alone PPH cases have been reported 3 / Early .

Drug dependence. Schedule IV designation reflects dependence potential. Psychological dependence (persistent urge to use the drug beyond the prescribed course) is more common than physical dependence. The sympathomimetic stimulant effect can create a positive-reinforcement pattern that makes discontinuation difficult for some patients.

Insomnia and sleep disruption. The stimulant properties cause insomnia when taken after midday. For perimenopausal women with hot-flash-related sleep disruption, phentermine adds to an existing sleep problem. Sleep deprivation is independently associated with cardiovascular risk, weight gain, and insulin resistance 5 / Solid . This interaction is clinically significant and underappreciated in the prescribing conversation.

Drug interactions. MAO inhibitors: absolute contraindication (hypertensive crisis). Other sympathomimetics: additive cardiovascular effects. Insulin and oral diabetes agents: dose adjustment may be required as glycemic control improves with weight loss.

8c. Who should not take phentermine

Absolute contraindications:

• Moderate to severe hypertension (systolic > 160 to 170 mmHg)
• Cardiovascular disease (established CAD, heart failure, significant arrhythmias)
• Hyperthyroidism
• Glaucoma
• History of drug abuse
• During or within 14 days of MAO inhibitor use
• Agitated states
• Known hypersensitivity to sympathomimetic amines

Clinical situations where I do not prescribe phentermine for women:

• Perimenopausal women with uncontrolled hypertension (blood pressure above 140/90) without prior blood pressure improvement, the sequencing is wrong
• Women with palpitations or arrhythmias that have not been evaluated (don’t add a sympathomimetic without a cardiac evaluation)
• Women with significant sleep disruption from hot flashes or insomnia (phentermine will worsen it)
• Women on tamoxifen (complex interaction: both tamoxifen and phentermine have cardiovascular and CNS effects that require specialist review; the interaction is not as clear-cut as the bupropion-tamoxifen CYP2D6 interaction, but it deserves attention)
• Women who were told phentermine is “just a diet pill” and have not been given the full cardiovascular risk profile, informed consent first, prescription second

8d. Common adverse effects

Dry mouth (most common), insomnia, irritability, palpitations, tachycardia, raised blood pressure, headache, dizziness, constipation, changes in libido. All are sympathomimetic effects. In perimenopausal women, insomnia, palpitations, and mood changes can be misattributed to menopause rather than to the drug, requiring careful symptom attribution at follow-up.

Clinical Decision-Making: Phentermine for Women

The sequencing problem

The most common clinical error with phentermine in perimenopausal women is sequencing: prescribing a sympathomimetic pressor drug before blood pressure is controlled. For Sandra, whose blood pressure was 144/88, the correct clinical sequence was:

1. Address the blood pressure (initiate antihypertensive therapy if not yet started)
2. Assess the full cardiac risk profile (ApoB, fasting insulin, consider Lp(a))
3. Discuss whether weight management pharmacotherapy is appropriate after blood pressure is controlled, and if so, which agent matches her specific phenotype

Phentermine might be appropriate for Sandra after blood pressure improvement. But it was not appropriate as the first intervention before blood pressure was addressed.

Patient selection rubric for women

1. Blood pressure controlled before starting. I will not prescribe phentermine to a woman whose systolic blood pressure is above 140 mmHg without a concurrent blood pressure management plan that includes monitoring.

2. Palpitations and arrhythmia evaluation. Any prior history of palpitations, irregular heartbeat, or documented arrhythmia requires an ECG and clinical cardiac evaluation before phentermine.

3. Hormonal context. Perimenopausal status affects the background noise for phentermine’s adverse effects. A woman already experiencing palpitations, sleep disruption, and mood changes from hormonal fluctuation needs specific counseling that phentermine may amplify all three. This is informed consent, not a contraindication.

4. Eating pattern. Phentermine targets hunger-driven eating. The woman whose primary driver is appetite, genuine, persistent hunger leading to large portions and frequent eating, is the mechanism-matched patient for phentermine. The woman whose primary driver is emotional eating, stress-driven eating, or food noise is better served by Contrave (food-noise circuit) or behavioral therapy.

5. Pregnancy status. Phentermine is Category X for pregnancy (FDA historical classification). The drug has teratogenic potential in animal models 5 / Solid . Phentermine must not be used in pregnancy. Women of reproductive potential require contraceptive counseling.

Pre-flight checklist

• Blood pressure measured today (not from a prior visit)
• Heart rate measured
• ECG if any prior palpitations or arrhythmia history
• Pregnancy test if any reproductive potential
• Current medication review for MAO inhibitors and antihypertensives
• Sleep quality assessment (phentermine-related insomnia risk stratification)
• ApoB and fasting lipids (to understand the full cardiac risk context)
• TSH (hyperthyroidism contraindication)

Monitoring protocol

Week 2: Blood pressure, heart rate, weight. Direct assessment of palpitations, insomnia, and mood changes. If blood pressure has increased more than 10 mmHg above baseline or palpitations are occurring, stop phentermine.

Week 6: Same as week 2 plus weight assessment. If weight loss is less than 4% of baseline, non-response is likely.

Week 12: Stop phentermine. The FDA label says “a few weeks.” Off-label continuation beyond 12 weeks is not supported by evidence and increases cardiovascular monitoring burden without a safety database to reference.

The palpitations management protocol

For a woman who experiences palpitations on phentermine:

1. Obtain a 12-lead ECG. Not a phone cardiogram. A clinic ECG.
2. If palpitations are brief and self-terminating, document rate and regularity at the time of the event (wearable monitor or palpation if available).
3. If palpitations are frequent or prolonged, consider 24-hour Holter monitor before continuing phentermine.
4. If palpitations are accompanied by syncope, chest pain, or shortness of breath, stop phentermine immediately and evaluate.

What to Do Now

Four concrete next steps for the woman who is on phentermine or was recently prescribed it:

Step 1: Get your blood pressure measured today. If you are currently taking phentermine and your blood pressure has not been measured since starting, measure it now. The acceptable threshold for continuing phentermine is a systolic below 160 mmHg. If your blood pressure is higher than that, contact your prescriber before taking another dose.

Step 2: Have the palpitations conversation. If you have experienced palpitations, racing heart, or irregular heartbeat while on phentermine, do not quietly stop the medication and move on. Have the clinical conversation: “I experienced palpitations on phentermine. I want a 12-lead ECG and a clinical assessment of whether those palpitations were drug-related, perimenopausal, or a separate cardiac issue.” This is a reasonable medical request, not an overreaction.

Step 3: Ask whether a GLP-1 RA is more appropriate for your cardiac risk profile. If you have blood pressure above 130/80, ApoB above 100, or any cardiovascular risk factors, a GLP-1 RA with CVOT evidence is the pharmacologically stronger choice. The specific question: “Given my blood pressure and metabolic profile, is semaglutide or another GLP-1 medication a better first choice than phentermine, and is there a prior authorization pathway or patient assistance program for it?”

References

1. Bohula EA, Wiviott SD, McGuire DK, et al. Cardiovascular safety of lorcaserin in overweight or obese patients (CAMELLIA-TIMI 61). N Engl J Med. 2018;379(12):1107-1117. DOI: 10.1056/NEJMoa1808228

2. Cappuccio FP, D’Elia L, Strazzullo P, Miller MA. Sleep duration and all-cause mortality: a systematic review and meta-analysis of prospective studies. Sleep. 2010;33(5):585-592. DOI: 10.1093/sleep/33.5.585

3. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337(9):581-588. DOI: 10.1056/NEJM199708283370901

4. Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovasc Res. 2002;53(3):688-708. DOI: 10.1016/S0008-6363(01)00527-2

5. Iorga A, Cunningham CM, Moazeni S, et al. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biol Sex Differ. 2017;8(1):33. DOI: 10.1186/s13293-017-0152-8

6. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. DOI: 10.1056/NEJMoa2307563

7. U.S. Food and Drug Administration. Adipex-P (phentermine hydrochloride) capsules/tablets prescribing information. KVK-Tech. Accessed via: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/085128s065lbl.pdf

8. U.S. Food and Drug Administration. Lomaira (phentermine hydrochloride) 8 mg tablets prescribing information. KVK-Tech. Accessed via: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/088816Orig1s000lbl.pdf

— Dr. Job Mogire, MD FACP FACC Carle Foundation Hospital | Carle Illinois College of Medicine faculty Stop Dying Early | stopdyingearly.com

The Women’s Signal Check is fifteen questions mapping the female cardiovascular risk pattern, including reproductive history, microvascular signals, and the factors standard risk calculators do not capture. It produces a specific starting point for your next clinical conversation.